Guardant Health (NASDAQ: GH) co-CEO sells 37,500 shares via family foundation

Rhea-AI Filing Summary

Guardant Health, Inc. (GH) reported that Co-Chief Executive Officer and director AmirAli Talasaz, through indirect ownership by the Talasaz Family Foundation, sold a total of 37,500 shares of common stock on August 21, 2026 in open-market or private transactions. The sales occurred in three weighted-average price tranches between $167.81 and $170.50 per share. The transactions were not reported as made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Net Seller: 37,500 shares

Net Sell 3 txns

Insider Talasaz AmirAli

Role Co-Chief Executive Officer

Sold 37,500 shs ($6.34M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	9,023	$168.1958	$1.52M
Sale	Common Stock F2	20,888	$169.1618	$3.53M
Sale	Common Stock F3	7,589	$170.2862	$1.29M

Holdings After Transaction: Common Stock — 37,500 shares (Indirect, Shares held by the Talasaz Family Foundation)

Footnotes (3)

1. F1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.81 to $168.60. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
2. F2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.87 to $169.73. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
3. F3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.88 to $170.50. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold (total): 37,500 shares Block 1 sale: 9,023 shares at $168.1958 per share Block 2 sale: 20,888 shares at $169.1618 per share +2 more

5 metrics

Shares sold (total) 37,500 shares Total GH common shares sold indirectly via Talasaz Family Foundation on August 21, 2026

Block 1 sale 9,023 shares at $168.1958 per share Weighted average price; trades ranged from $167.81 to $168.60

Block 2 sale 20,888 shares at $169.1618 per share Weighted average price; trades ranged from $168.87 to $169.73

Block 3 sale 7,589 shares at $170.2862 per share Weighted average price; trades ranged from $169.88 to $170.50

Transaction date August 21, 2026 Date of all three reported sale transactions

Key Terms

weighted average sales price per share, indirect, open market or private transaction

3 terms

weighted average sales price per share financial

"Represents the weighted average sales price per share. These shares were sold"

indirect financial

"direct_or_indirect": "I", "nature_of_ownership": "Shares held by the Talasaz"

open market or private transaction financial

"transaction_code_description": "Sale in open market or private transaction""

FAQ

What insider transactions did GH disclose for AmirAli Talasaz on August 21, 2026?

GH disclosed that 37,500 shares of common stock were sold indirectly for the benefit of AmirAli Talasaz, via the Talasaz Family Foundation, in three open-market or private transactions on August 21, 2026.

At what prices were the GH shares sold in the Talasaz Family Foundation transactions?

The 37,500 GH shares were sold at weighted-average prices of $168.20, $169.16, and $170.29 per share, across ranges from $167.81–$170.50, as disclosed for each transaction block.

Were the August 21, 2026 GH share sales by the Talasaz Family Foundation under a Rule 10b5-1 plan?

No. The filing indicates the transactions were not reported as pursuant to a Rule 10b5-1 trading plan; the related checkbox affirming a plan was not selected.

Were the GH shares sold directly by AmirAli Talasaz or through an entity?

The sales were reported as indirect ownership transactions. The shares were held and sold by the Talasaz Family Foundation, with AmirAli Talasaz reporting them as an associated insider.

How many separate GH share sale transactions did the Talasaz Family Foundation report?

The Form 4 reports three separate non-derivative sale transactions of GH common stock on August 21, 2026, each with its own share amount and weighted-average price range.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/24/2026 - 05:22 PM Accepted by SEC EDGAR 08/24/2026 - 05:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Talasaz AmirAli

(Last) (First) (Middle)

3100 HANOVER STREET

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Guardant Health, Inc. [ GH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2026		S		9,023	D	$168.1958(1)	65,977	I	Shares held by the Talasaz Family Foundation
Common Stock	08/21/2026		S		20,888	D	$169.1618(2)	45,089	I	Shares held by the Talasaz Family Foundation
Common Stock	08/21/2026		S		7,589	D	$170.2862(3)	37,500	I	Shares held by the Talasaz Family Foundation

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.81 to $168.60. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

2. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $168.87 to $169.73. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.88 to $170.50. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ John G. Saia, as attorney-in-fact for AmirAli Talasaz	08/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)